67 results about "Immune Cell Function" patented technology

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function.

The invention provides a kit and a method for comprehensively evaluating functions of immune cells in human peripheral blood. The kit for comprehensively evaluating the functions of the immune cells in the human peripheral blood comprises an anti-human CD3, CD4, CD8, CD19, CD21, CD24, CD25, CD27, CD28, CD38, CD56, CD57, CD94, CD127, CD45RA, CXCR3, CXCR5, CCR4, CCR6, CCR7, HLA-DR, PD-1, P30, P46, NKG2D, KIR (NKB1), gamma delta, v delta 2, IgD and IgM antibodies, wherein the antibodies carry fluorescein labels. The kit can be used for comprehensively evaluating the functions of the immune cellsin the human peripheral blood, and is convenient and safe to use.

The invention discloses a transgenic T cell of a targeted CD30 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding the targeted CD30 antigen, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell containing a recombinant lentivirus expression vector (including a gene which is shown as SEQ ID NO:2 and encodes the targeted CD30 antigen and shRNA of a targeted PD1 gene or / and shRNA of a targeted CTLA4 gene); the primary cell is CD4+T cell or CD8+T cell. A preparation method comprises the following steps: firstly, carryingout lentivirus infection on the CD4+T cell or the CD8+T cell; secondly, mixing gRNA, CRISPR-cas9mRNA and HDR, and carrying out electroporation recombination on the T cell to obtain a finished product.According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are knocked out or silenced, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

The invention belongs to the technical field of Chinese herbal medicine and relates to externally applied medicine for treating beriberi and a preparation method of the externally applied medicine. The externally applied medicine solves the technical problems that the compatibility is not reasonable enough and the curative effect is poor in the prior art. The externally applied medicine comprises the following components in parts by weight: 1-3 parts of fructus cnidii, 4-6 parts of folium artemisiae argyi, 1-3 parts of radix angelicae pubescentis, 2-4 parts of grassleaf sweelflag rhizome, 2-4 parts of rhizoma atractylodis, 8-12 parts of mint, 4-6 parts of amoorcorn tree bark, 4-6 parts of radix scutellariae, 2-4 parts of radix sophorae flavescentis, 1-3 parts of fructus kochiae, 4-6 parts of oriental wormwood, 2-4 parts of gardenia, 12-18 parts of honeysuckle, 8-12 parts of ginger, 2-4 parts of tea, 1-3 parts of radix stemonae, 4-6 parts of Chinese lobelia, 4-6 parts of tuber fleeceflower stems, and 10-14 parts of rice vinegar. The externally applied medicine has the advantages that the externally applied medicine has the effects of alleviating pain, stopping pyemia, sterilizing, preventing inflammation and viruses, removing necrotic tissues, promoting tissue regeneration and improving immune cell functions. In addition, the externally applied medicine is simple to manufacture, low in cost, good in effect and suitable for industrial processing and production.

The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and / or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and / or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and / or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormone.

The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and / or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and / or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and / or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormon.

The invention discloses a killer immune cell culturing method and application thereof. The method is a novel technology for culturing, activating and amplifying peripheral blood mononuclear immune cells into tumor killer cells, and the tumor killing capacity of T cells is enhanced by adding a PD-1 antibody to inhibit combination of PD-1 on the T cells and tumor cells in the late period of cell culturing or before transfusion through the characteristic that the inhibition effect of an immunosuppression target point on the immune cell functions is inhibited by adding an immune check point antibody; the cells cultured through the method have CTL cells which are targeted on the tumor antigen specificity in high proportion and also have the high capacity on killing the tumor cells. In this way, not only is the defect of an existing technology on the CTL cell culturing effect overcome, but also limitation of an immune checking point on the T cell functions is fully utilized and relieved, therefore, the tumor cell killing capacity of the prepared cells is improved, and the efficacy of the prepared cells on clinical cancer treatment is improved.

The invention discloses a transgenic T cell of a targeted CD19 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:8 and encoding the targeted CD19 antigen in chromosome, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding a targeted PSA-NCAM receptor ,and a gene shown asSEQ ID NO:8 and encoding the targeted CD19 antigen in the chromosome; the primary cell is CD4+T cell or CD8+T cell. The invention also discloses application of the transgenic T cell of the targeted CD19 antigen in preparation of a medicine for treating malignant B cell lymphoma. According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are silenced or knocked out, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

The invention discloses a construction method and application of a CD45-DTR transgenic mouse for regulating and removing immune cells by diphtheria toxin. The preparation method comprises the following steps: performing enzyme digestion linearization on BAC Cone CD45-DTR; introducing BALB / C ES cells of mouse embryonic stem cells by using an electroporation method to obtain the BALB / C ES cells withIRES-DTR being inserted into the site 1 of the CD45 exon; and then, constructing a CD45-DTR transgenic mouse with the IRES-DTR being inserted into the site 1 of the CD45 exon through a blastocyst injection method by utilizing the BALB / C ES cells. The invention provides a novel construction method of a mouse model capable of inducing and selectively removing immune cells. The method can be widelyapplied to the fields of preparation of humanized mice, research of immune cell functions and the like.

The invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INFα, and IFNγ. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug. When the multifunctionality of immune cells treated with the biguanide antidiabetic drug selected from metformin, phenformin, and buformin is determined to be significantly increased compared with the control, it can be evaluated that the sensitivity of the immune cells to the therapeutic agent is improved.

The invention provides an antibacterial ceramic product, which comprises a main body layer, a glaze layer and energy mineral powder, wherein the glaze layer is in contact with the main body layer; and the energy mineral powder is dispersed into the main body layer or the glaze layer. The energy mineral powder is added to the antibacterial ceramic product and can release 4-16micron far infrared rays; the released far infrared rays can release heat; the pathological process of inflammation is removed through question and answer reaction of a neurohumour; the physiological balance state damaged in the past is restored; local and whole-body disease resistance is improved; the immunologic cell function is activated; the phagocytic function of white blood cells and reticuloendothelial cells is reinforced; the antibacterial and anti-inflammation effects are finally achieved, so that the antibacterial ceramic product provided by the invention has a healthcare effect; the preparation method of the antibacterial ceramic product provided by the invention is simple in process and easy to operate; and large-scale manufacturing production is facilitated.

Methods for generating highly enriched Th1 / Tc1 and Th2 / Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.

The invention discloses a chimeric antigen receptor. The chimeric antigen receptor comprises: a) an extracellular target molecule binding motif; b) an intracellular signal transduction motif, which comprises at least one intracellular activation signal transduction motif, wherein the activation of the intracellular activation signal transduction motif at least depends on binding of the extracellular target molecule binding motif to a target molecule, and the intracellular activation signal transduction motif contains molecules or fragments with catalytic functional groups; and c) a transmembrane region motif for linking the extracellular target molecule binding motif and the intracellular signal transduction motif. The chimeric antigen receptor is combined with various means such as tumorimmunology, synthetic biology, molecular cell engineering and the like, an artificial molecular machine which is based on an immune checkpoint signal path PD-1 / PD-L1 and has a function of coding and regulating immune cells is established and applied, and the chimeric antigen receptor has the same advantages as both an immune checkpoint inhibitor and CART cell therapy and provides a solution for improving solid tumor treatment.